Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC for Inflammatory or Recurrent Breast Cancer
NCT02658812Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial of talimogene laherparepvec in inflammatory breast cancer (IBC) and recurrent breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2016; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
inflammatory breast cancer (IBC)recurrent breast cancer
Beyond the preview
Go deeper on NCT02658812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02658812.